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Outcomes with autologous hematopoietic cell transplantation (auto HCT) for relapsed and/or refractory
mantle cell lymphoma (MCL) are typically poor. We hypothesized that certain factors could predict which
patients experience a favorable outcome with this approach. We thus developed a predictive score from
a cohort of 67 such patients using 3 factors independently associated with progression-free survival (PFS): (1)
simpliﬁed Mantle Cell Lymphoma International Prognostic Index score before auto HCT (hazard ratio [HR],
2.9; P ¼ .002); (2) B symptoms at diagnosis (HR, 2.7; P ¼ .005); and (3) remission quotient, calculated by
dividing the time, in months, from diagnosis to auto HCT by the number of prior treatments (HR, 1.4; P ¼ .02).
The estimated 5-year PFS for favorable-risk patients (n ¼ 23) and unfavorable-risk patients (n ¼ 44) were 58%
(95% conﬁdence interval [CI], 34% to 75%) and 15% (95% CI, 6% to 28%), respectively. These factors also
independently predicted overall survival. In summary, we have deﬁned 3 simple factors that can identify
patients with relapsed/refractory MCL who derive a durable beneﬁt from salvage auto HCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Mantle cell lymphoma (MCL) is a unique form of B cell
non-Hodgkin lymphoma, with features of both indolent and
aggressive histologies. The majority of patients present with
advanced-stage disease, which is not felt to be curable with
conventional treatment [1]. Despite advances in treatment
and supportive care, the median survival after diagnosis of
MCL with modern approaches is only about 5 years [2].
Moreover, there is a wide range in the clinical courses
observed with this lymphoma, with some patients dying
from their disease within 1 to 2 years of diagnosis despite
very aggressive treatment, whereas others live for a decade
or longer without receiving such potent therapies.
Because of this relatively poor prognosis, much effort has
been made to improve the outcomes of patients with
advanced MCL. Consolidation with autologous hematopoi-
etic cell transplantation (auto HCT) after induction therapy
has emerged as a promising strategy for prolonging remis-
sions [3-8]. In contrast, the use of auto HCT in patients with
relapsed or refractory disease has generally not been asso-
ciated with favorable outcomes [9-11]. We have observed
that a subset of these patients can have prolonged survivaldgments on page 1406.
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13.07.005after auto HCT, which led us to identify factors characterizing
these patients. This approach could be beneﬁcial in that
patients who are destined to do poorly could be spared from
the morbidity, mortality, and expense of auto HCT;
conversely, patients likely to do well after transplantation
could be encouraged to consider this as a viable treatment
option.
Therefore, we gathered data from patients with MCL
beyond ﬁrst remission who received this treatment at our
center. We examined characteristics both from the time of
diagnosis and from their evaluation immediately before auto
HCT. From this information, we sought to deﬁne speciﬁc
features that identify patients with relapsed or refractory
MCL who would beneﬁt most from auto HCT.
MATERIALS AND METHODS
Patient Selection
Records from consecutive patients older than 18 years with MCL
receiving auto HCT between April 1996 and February 2011 at the Fred
Hutchinson Cancer Research Center, University of Washington Medical
Center and Veterans Affairs Puget Sound Health Care System (Seattle,
Washington) were reviewed. Patients who received a planned tandem
autologous-allogeneic transplant or a syngeneic transplant were excluded.
All authors had access to the primary clinical data. The institutional review
board of Fred Hutchinson Cancer Research Center approved this minimal-
risk study.
Data Collection and Deﬁnitions
Relapsed/refractory MCL was deﬁned as 1 relapse or unable to achieve
a remission before auto HCT. Simpliﬁed Mantle Cell Lymphoma Interna-
tional Prognostic Index (sMIPI) scores were calculated using data from
diagnosis, as well as before conditioning therapy for auto HCT (sMIPI-Auto)
Table 1
Demographics of Patients with Relapsed or Refractory Mantle Cell
Lymphoma from the Time of Diagnosis and Autologous Hematopoietic Cell
Transplantation


























LDH/ULN, median (range) 1.0 (.5 to 10.6)
WBC (109/L), median (range) 7.4 (1.8 to 54.7)
sMIPI-Dx
0 to 2 12 (18%)
3 8 (12%)
4 to 5 14 (21%)
6 10 (15%)
Unable to calculate 23 (34%)
Characteristics at Auto HCT No. (%)
Age, median (range), yr 58 (41 to 70)
Time from diagnosis to Auto HCT,
median (range), mo
25 (4 to 183)
Number of prior systemic therapies,
median (range)



















LDH/ULN, median (range)y .9 (.6 to 1.8)
WBC (109/L), median (range) 4.8 (.5 to 17.6)
sMIPI-Autoy
0 to 2 26 (39%)
3 28 (42%)
4 to 5 12 (18%)
6 1 (1%)
Unable to calculate 0
Auto HCT indicates autologous hematopoietic cell transplantation; sMIPI,
simpliﬁed Mantle Cell Lymphoma International Prognostic Index score;
sMIPI-Dx, sMIPI score at diagnosis; sMIPI-Auto, sMIPI score before condi-
tioning therapy for auto HCT; CR, complete remission; ECOG, Eastern
Cooperative Oncology Group; LDH, lactate dehydrogenase; PET, positron
emission tomography; PR, partial remission; SD, stable disease; sMIPI,
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(OS) were deﬁned by standard criteria [13]. Patients were considered to have
chemo-sensitive disease if they achieved either a complete or partial remis-
sion to the most recently administered systemic therapy before trans-
plantation. Follow-up was updated as of December 2012.Statistical Analysis
Kaplan-Meier curves were used to estimate the probabilities of OS and
PFS. The statistical signiﬁcance of differences in event rates was evaluated
with the proportional hazards regression model. For comparisons in which
no events were observed in a group, a generalized Wilcoxon test was
applied. Reported P values are based on the Wald statistic. Statistical anal-
yses were performed using SAS Version 9.3 (SAS Institute Inc., Cary, NC).RESULTS
From a cohort of 165 patients with MCL treated with auto
HCT at our center, 67 (41%) met the prespeciﬁed deﬁnition of
relapsed/refractory MCL. Their characteristics are described
in Table 1. Most patients (84%) were male, and 9 (16%) of the
56 patients with relevant data had blastoid variant patho-
logic subtype. The vast majority (93%) had stage III or IV
disease at diagnosis. At the time of auto HCT, the median age
was 58 years (range, 41 to 70 years), and 76% of patients were
in either complete or partial remission. At last contact, 25
(37%) of 67 patients were alive, and 16 patients (24%) were
alive and progression free, with a median follow-up time for
surviving patients of 5.1 years (range, .1 to 16.0 years;
Figure 1A).
All factors in Table 1 were considered as potential
predictors in a multivariable model. The same 3 factors were
identiﬁed as independent predictors of worse PFS and OS:
higher sMIPI-Auto (hazard ratio [HR], 2.9 for PFS; P ¼ .002;
HR,1.9 for OS; P¼ .003); presence of B symptoms at diagnosis
(HR, 2.7 for PFS; P ¼ .005; HR, 2.5 for OS; P ¼ .008); and
a lower remission quotient (RQ), calculated by dividing the
time in months from diagnosis to auto HCT by the number of
prior treatments (HR, 1.4 for PFS; P ¼ .02; HR, 1.8 for OS; P ¼
.002). Patients with blastoid histology are generally felt to
have a worse prognosis, and indeed, they did have signiﬁ-
cantly inferior PFS in a univariate analysis (HR, 3.2; P ¼ .007).
However, their OS was not signiﬁcantly worse by univariate
analysis (HR, 2.0; P ¼ .12) and, again, this factor did not
emerge from our multivariable model.
The estimated linear predictors from this multivariable
model were used to formulate a predictive score for OS and
PFS. The lowest tertile of linear predictors deﬁned a subset of
23 patients (34%) with relatively low risk of death and/or
progression (Figure 1B,C). The favorable-risk group met the
following criteria: (1) sMIPI-Auto  2, no B symptoms, and
RQ  6; (2) sMIPI-Auto  2, B symptoms present, and
RQ  13; or (3) sMIPI-Auto 3, no B symptoms, and RQ  13.simpliﬁed mantle cell lymphoma international prognostic index; ULN,
upper limit of normal.
Data are presented as n (%) unless otherwise indicated.
* The number of patients with SD/untested relapse is not equal to the
number of patients with chemo-refractory disease for the following reason:
there were 3 patients who had an isolated site of disease that failed to
respond to the most recently-administered systemic therapy, but achieved
remission following locally-directed interventions (2 received salvage
radiotherapy, and 1 underwent splenectomy). Further, there were 5
patients with chemo-sensitive disease who were taken to auto HCT in
untested relapse.
y The upper limit of normal was unknown for 2 LDH measurements from
the time of auto HCT, resulting in missing values of median LDH/ULN for
these patients; based on other available data, both of these patients were
assigned sMIPI-Auto values of 2.
Figure 1. Kaplan-Meier survival curves for patients with relapsed or refractory
mantle cell lymphoma treated with autologous hematopoietic cell trans-
plantation. (A) Progression-free and overall survival curves for the 67 patients
evaluated in this study. Tick marks represent censoring times. (B) Progression-
free and (C) overall survival when stratiﬁed by predictive score, which was
derived from a multivariable model containing simpliﬁed MIPI score at the
time of transplantation (P ¼ .002), the presence of B symptoms (P ¼ .005), and
the remission quotient (P ¼ .02), calculated by dividing the time, in months,
from diagnosis to transplantation by the number of prior treatments; see text
for further deﬁnition of these risk scores.
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either sMIPI-Auto  4 or RQ < 6 (independent of the other
factors), were predicted to do poorly (Figure 1B,C). TheKaplan-Meier 5-year estimates for PFS were 58% (95% CI, 34%
to 75%) for the favorable-risk group and 15% (95% CI, 6% to
28%) for the unfavorable-risk group; the 5-year estimates for
OS were 76% (95% CI, 48% to 89%) and 32% (95% CI, 19% to
46%), respectively.DISCUSSION
There is an increasing amount of controversy surrounding
the optimal management of MCL and, in particular, the role
of auto HCT. This represents one of the largest series to date
that explicitly describes the outcome of auto HCT for
relapsed/refractory MCL. This subgroup represents a rela-
tively large proportion (41%) of patients with MCL who have
been treated with auto HCT at our center. Registry data from
the Center for International Blood and Marrow Transplant
Research found a comparable proportion of patients under-
going auto HCT had “late” MCL (ie, more than 2 prior
chemotherapy regimens) [14]. Referral bias and/or follow-up
from an era that predates this approach may account for this
ﬁnding.
A unique feature described in this report is the RQ. This
term was derived to quantify what is often observed clini-
cally: both the number of prior therapies and the duration
of remissions contribute to outcomes. This has not been
deﬁned previously to our knowledge, and it is a straight-
forward metric to gauge the natural history of malignancies
that have a predilection toward multiple relapses. As such,
it may have applicability for malignancies other than MCL.
Validation of this measure in other studies will help
determine its utility.
This combination of sMIPI-Auto, B symptoms, and RQ
represents a novel method for discriminating which patients
with relapsed/refractory MCL are most likely to beneﬁt from
auto HCT. We feel that this adds substantially to the results
from the Center for International Blood and Marrow Trans-
plant Research noted above [14]. These authors estimated
the 5-year PFS after auto HCT for patients with chemo-
sensitive late MCL to be 49% (n ¼ 159). This result is
slightly inferior to that predicted by our model for patients
with favorable-risk features (ie, estimated 5-year PFS of 58%).
Perhaps more important, though, is our deﬁnition of
a subgroup of unfavorable-risk patients, for whom the
outcome of auto HCT is likely not worth its associated risks
(Figure 1B,C).
One of the most attractive features of this risk-
stratiﬁcation system is that these 3 factors are readily avail-
able to any clinician. Therewere not sufﬁcient data to include
Ki-67 or positron emission tomography results in our
models, although they have been shown by others to be
signiﬁcant [4,12,15-17]. It is noteworthy that remission status
and blastoid histology were not signiﬁcant in our multivar-
iable model, although their association with outcomes in
MCL are frequently cited [4,11,17]. Perhaps the sMIPI-Auto, B
symptoms, and RQ capture similar biologic or clinical
features that these other factors describe.
This analysis does have several notable limitations. First,
because of the nature of this analysis, we were only able to
account for patients who underwent auto HCT. This risk-
stratiﬁcation system, therefore, could also be predictive of
outcomes after treatments other than auto HCT. Second,
because of the long follow-up available, the impact of newer
induction strategies, novel targeted agents, and post-HCT
maintenance strategies could not be fully addressed. Lastly,
though this cohort is relatively large, the relatively small
R.D. Cassaday / Biol Blood Marrow Transplant 19 (2013) 1393e14111406numbers in certain subgroups of interest (eg, blastoid
histology) limits some of our ﬁndings.
In conclusion, we have described a novel predictive score
based on readily available factors that may be useful in iden-
tifying patients with MCL beyond ﬁrst remission most likely
to beneﬁt from auto HCT. As non-HCTebased options for
front-line therapy improve [18,19], more patients or providers
may decline an HCT-based approach as initial treatment.
However, when relapse occurs, this predictive model could
help clarify the role of auto HCT as salvage therapy. Future
studies will need to validate these ﬁndings and determine
if they can be used to guide clinical decision-making to
improve the treatments available to patients with MCL.
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